TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall Response Rate by Blinded Independent Review Committee (BIRC) per RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of investigational treatment related severe toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience At Least One adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of re-stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Negative predictive value of POCUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total drug exposure to the last measurable concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak drug concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of invasive mechanical ventilation at the first 72 hours of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Hand Function Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Cardiac Amyloidosis Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Karnofsky Performance Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biochemical Markers Related to Bone Metabolism and Inflammatory Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to diagnosis of anastomotic leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lipoprotein (a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EEG Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence or absence of persistent post-concussive symptoms (PPCS) 30 days after injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence or absence of concussion recovery 30 days after injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inguinal lymph node volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Walther standard synovial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alder blood flow indexing standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation of biomarker release with LGE cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time weighted average mean arterial pressure within treatment arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Within treatment arm % of total group with a composite MACE event in the 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average within treatment arm total minutes under 92% oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease or clearance in baseline ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects with complete response (SDAS = 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of methylated gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Sum of Pain Intensity Difference Over 6 Hours (SPID0-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean monocular best corrected distance visual acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of functional anorectal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cerebral Hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in WOMAC Osteoarthritis Index pain subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia impact questionnaire (FIQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline plasma NGAL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolic health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in inflammatory condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sharpened Romberg (SR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Douleur Neuropathique 4 (DN4) Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unilateral stance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Falls Efficacy Scale International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful tumour growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative RNA biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Most Bothersome Symptom (MBS) Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pain experienced during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with severe mpox
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal cardiac remodeling and dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reaction time and sustained attention (composite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive benefit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nottingham Health profile
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: National Institute of Ophthalmology Visual Function Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Mini-Mental Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: molecular alteration profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Location of evoked sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulation threshold range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the participants
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Biopsy Proven Acute Rejection at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Usability of the graphical user interface
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Referral rate of patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Surgeon referral order rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants with solicited injection-site adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with solicited systemic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with vaccine-related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Questions about sexual behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Western Aphasia Battery Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of neutropenic fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caries experience (DMFT score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state area under the concentration-time profile (AUC24) for danuglipron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state maximum observed concentration (Cmax) for danuglipron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state time to reach maximum observed concentration (Tmax) for danuglipron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge level of nursing students
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of subjects with a prostate-specific antigen decline of >90% (PSA90) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants experiencing a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants discontinuing study treatment due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Mental Health Questionnaire Lluch
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Slalom dribble test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harre circuit test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile Plethysmography/Phallometric Testing (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rating Anxiety Scale (SAS) scores change (%)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neck region muscle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change on Recovery Experience Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Allergic rhinitis knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inhaler technique proficiency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of COVID
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IV morphine equivalent (MME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in revised Patterson edema scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in Forced Vital Capacity (FVC) % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of Low back pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of functional disability related to low back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak torque measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eradication of N. meningitidis carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Japanese Encephalitis Virus seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Upper limbs scales reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb scales reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health scales and autonomy reliability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive change in miLens output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of miLens output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of miLens
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the oral microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: High-risk polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Paediatric usual values for hormones dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Dry Skin/Ichthyosis Area and Severity Index (DASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in SCORAD severity scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in Eczema Area and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in visual assessment of post inflammatory hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of participants video completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in graded evaluation of exercises by pelvic floor therapist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in sleep stages N2 + N3
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Quality of Life-Lite survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Humanistic care competence of nursing students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VWF-Ag concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Finger to Floor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of long-term endoscopic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Responded Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Participants who discontinued due to an adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Intravascular Attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Rocatinlimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration Time Curve (AUC) from Time Zero to the Time of the Last Measurable Concentration (AUClast) of Rocatinlimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from Time Zero to Infinity (AUCinf) of Rocatinlimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Depression severity measured by PHQ9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Opioid Consumption 72 Hours Post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Port Access Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinic Wait Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of Visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in Quality of Life Measurement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vault height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Management Health Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage change in CLASI-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of six-minute walk test (6MMWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gene Expression Alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cytokine Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of autofluorescence (FAF) laser-light spot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of NIR-cSLO laser-light spot traces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to active IMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction among active IMR participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of completer status
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Days of Alcohol Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Standard Drinks Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-related adverse events (TRAEs) leading to study treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per investigator assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hematologic VGPR + CR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systemic embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New endocarditis event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of radiographic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of clinical outcome by resolution of clinical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale-6 Items
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ambulance use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cervical obstructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of Intracranial Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurologic Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of serum Elafin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brockport Physical Fitness Test (BPFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verran and Snyder-Halpern Sleep Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rate of grade 3 and higher grade treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: adherence to dTMS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-report dental anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratio of geometric mean titers (GMTs) of each strain at 1-month post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median time to sustained symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathological complete remission rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flap viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in treatment responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary metabolomic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Perception in Quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turning velocity (degrees/second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps taken during turning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turning step length (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes